Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories

MLA

Masanobu Ishii, et al. “Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories.” JACC: Asia, vol. 2, Dec. 2022, pp. 882–93. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....55d8688da58db399dc658744ebcc2194&authtype=sso&custid=ns315887.

APA

Masanobu Ishii, Koichi Kaikita, Satoshi Yasuda, Masaharu Akao, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa, & Kenichi Tsujita. (2022). Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories. JACC: Asia, 2, 882–893.

Chicago

Masanobu Ishii, Koichi Kaikita, Satoshi Yasuda, Masaharu Akao, Junya Ako, Tetsuya Matoba, Masato Nakamura, et al. 2022. “Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories.” JACC: Asia 2 (December): 882–93. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....55d8688da58db399dc658744ebcc2194&authtype=sso&custid=ns315887.